Greysun is the lead guides editor at Game Rant, covering all the biggest AAA titles to the smaller indie gems. He's been a big Nintendo fan since the SNES days and patiently awaits a Super Mario ...
Hoth continues to advance HT-001 in its Phase 2 CLEER-001 clinical trial targeting EGFR-inhibitor–associated rash, a significant unmet need in oncology supportive care. Recent progress includes: ...
Hoth is broken. As a closet Imperial, it just feels cruel. Yes, the Empire won Hoth. Despite Admiral Ozzel's incompetence, Hoth wasn't just a victory for the Empire, it was a massacre. But Battlefront ...
You can trust VideoGamer. Our team of gaming experts spend hours testing and reviewing the latest games, to ensure you're reading the most comprehensive guide possible. Rest assured, all imagery and ...
Hoth has submitted a Clinical Trial Application (CTA) to the European Medicines Agency (EMA) to expand its ongoing Phase II trial of HT-001, a novel topical therapeutic for EGFR inhibitor-induced skin ...
The average one-year price target for Hoth Therapeutics (NasdaqCM:HOTH) has been revised to $4.59 / share. This is an increase of 12.50% from the prior estimate of $4.08 dated November 14, 2025. The ...
100% of Patients in Cohort 1 Achieve Primary Efficacy Endpoint No Treatment-Related Adverse Effects Observed Preserves Cancer Treatment Efficacy with Zero Dose Reductions NEW YORK, Jan. 7, 2025 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback